At a glance
ClinicalIndex Comparison Record- ✓Female and male patients aged ≥18 years with stage I-III non-metastatic breast cancer
- ✓Completed neoadjuvant chemotherapy, surgery, and standard post-neoadjuvant treatment ± radiotherapy
- ✓TNBC or HER2-positive with non-pCR (ypT0/is ypN0)
- ✓HR-positive HER2-negative with non-pCR and CPS-EG score ≥3 with ypN0 or ≥2 with ypN+
- ✕Other malignancy within 5 years except non-melanoma skin cancer, in situ cervical cancer, DCIS, Stage 1 grade 1 endometrial carcinoma, or curatively treated solid tumors with ≥5 year disease-free survival
- ✕Concurrent severe uncontrolled systemic disease
- ✕Concurrent participation or prior treatment in another interventional trial within 30 days
- ✕Persistent Grade ≥2 toxicity from prior cancer therapy (excluding alopecia)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE
In Brief
A Phase 2 clinical trial evaluating Atezolizumab 1200 mg in 20 ML Injection, Inavolisib, and 4 other interventions for Early-stage Breast Cancer. Currently recruiting, targeting 240 participants across 9 sites.
Signals
Detailed Summary
In early breast cancer (eBC), pathological complete response (pCR) after neoadjuvant therapy acts as surrogate marker for metastasis and overall survival. Therapy intensification by adding an adjuvant therapy line (post-neoadjuvant treatment) substantially lowers the risk of relapse in high-risk breast cancer patients with residual disease after neoadjuvant treatment (non-pCR). While this approach was exemplified in two phase III trials without biomarker-stratification (CREATE-X, KATHERINE), even higher efficiency might be achieved by individualized genomic-guided post-neoadjuvant therapies. Within the seven-arm umbrella phase-II clinical trial COGNITION-GUIDE, we aim to deliver molecularly-tailored cancer care by implementing an additional response- and genomics-guided post-neoadjuvant therapy after finishing the guideline-compliant post-neoadjuvant treatment in high-risk breast cancer patients with residual cancer burden after neoadjuvant therapy to reduce the substantial risk of local and distant relapse. The trial evaluates not a single drug but rather a general strategy of precision oncology in the curative setting and provides the basis for future confirmatory biomarker-driven trials. Allocation to the therapy-arms is conducted by in depth molecular characterization of tumors within the COGNITION registry program. The study aims to show an overall benefit of the precision medicine approach in high-risk eBC patients and to allow for secondary exploratory evaluation of each study-arm. The primary endpoint of the study is invasive Disease-Free Survival (IDFS) after 4 years measured from surgery to local or distant relapse or death. The sample size of the entire trial is 240 eligible patients.
Study Details
Timeline
Interventions
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6